Eli Lilly and Co. may have found a new use for its osteoporosis drug Evista, according to Bloomberg.
The U.S. Food and Drug Administration said Evista reduced the risk of certain invasive breast cancers in post-menopausal women.
However, studies from Indianapolis-based Lilly provided weaker support for Evista’s ability to help women at high risk of developing breast cancer, the FDA said.
Evista is a $1 billion a year drug, but Lilly wants to find new uses for it because analysts expect its sales to tail off gradually over the next several years. Lilly has a patent on Evista until 2014.